University of Limerick Institutional Repository

The real-world use of different anti-tumor necrosis factor agents in a Northern European population of patients with Behçet's disease

DSpace Repository

Show simple item record Adeeb, Fahd Ng, Wan Lin Usman Khan, Maria Devlin, Joseph Stack, Austin G. Fraser, Alexander D. 2018-03-14T11:29:27Z 2018-03-14T11:29:27Z 2017
dc.description peer-reviewed en_US
dc.description.abstract Objective: The aim of this study was to evaluate prescription practices, treatment responses, and serious adverse events of anti-tumor necrosis factor (anti-TNF) therapies in Behcet's disease (BD).Material and Methods: Patients with BD satisfying the International Study Group for Behçet's Disease or the International Criteria for Behcet's Disease criteria were recruited from a regional rheumatology program. The choice of anti-TNF, treatment response, and adverse events were specified. Response to treatment was evaluated by the detection of new, worsening, or improving clinical features, and management was benchmarked against current The European League against Rheumatism recommendations published in 2008.Results: Out of the total of 22 patients, 18 (81.9%) received anti-TNF therapies, resulting in 14 (77.8%) complete and 4 (22.2%) partial remissions. Eleven (61.1%) patients switched to a second anti-TNF, seven patients (38.9%) required three different anti-TNFs, and one required a fourth anti-TNF to achieve remission. Two patients required retrials before their disease was controlled. Anti-TNF therapy included infliximab (IFX): n=15, 83.3%; adalimumab (ADA): n=9, 50%; golimumab: n=6, 33.3%; etanercept: n=5, 27.8%; and certolizumab pegol: n=2, 11.1%. Secondary failure was observed with IFX (4/15; 26.7%) and ADA (2/9; 22.2%), and these (100%) were manifested after at least 2 years of treatment. Five patients with potentially life-threatening laryngeal involvement received anti-TNFs successfully halting disease progression. Five allergic reactions were encountered, and five serious infections were documented involving three patients aged ≥ = 50 years, all with the use of IFX.Conclusion: Anti-TNF therapy induced a clinical response in 100% patients and achieved complete remission in 78% patients. It provides an effective alternative option for first-line therapy in severe BD where many conventional immunosuppressive therapies fail. Patients with BD who do not respond to one or more anti-TNFs because of intolerance, ineffectiveness, or secondary failure might benefit from switching to another drug from this group or even a retrial of a previously administered anti-TNF because unsatisfactory results with one biologic is not predictive of response to another anti-TNF. For those with potentially life-threatening destructive laryngeal manifestation, anti-TNF as a first choice may be considered. en_US
dc.language.iso eng en_US
dc.relation.ispartofseries European Journal of Rheumatology: 4 (4), pp. 254-259
dc.subject biologics en_US
dc.subject anti-TNF en_US
dc.subject TNF-alpha en_US
dc.subject Behçet's disease en_US
dc.subject Behçet's syndrome en_US
dc.title The real-world use of different anti-tumor necrosis factor agents in a Northern European population of patients with Behçet's disease en_US
dc.type info:eu-repo/semantics/article en_US
dc.type.supercollection all_ul_research en_US
dc.type.supercollection ul_published_reviewed en_US 2018-03-14T11:17:03Z
dc.description.version PUBLISHED
dc.identifier.doi 10.5152/eurjrheum.2017.17046
dc.rights.accessrights info:eu-repo/semantics/openAccess en_US
dc.internal.rssid 2736010
dc.internal.copyrightchecked Yes
dc.identifier.journaltitle European Journal Of Rheumatology
dc.description.status peer-reviewed

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ULIR


My Account